Table 4.

Summary of VHL gene inactivation mechanism by best overall response (RECIST v1.0) in patients from both treatment arms combined

	No. of patients (%)
	CR (n = 1)	PR (n = 51)	SD (n = 64)	PD (n = 23)
Overall VHL gene inactivation status
Yes	0	41 (80)	45 (70)	18 (78)
No	0	5 (10)	10 (16)	2 (9)
VHL mutation inactivation status
Yes	0	36 (71)	40 (62)	14 (61)
No	1 (100)	12 (24)	18 (28)	7 (30)
VHL large deletion status
Yes	0	4 (8)	1 (2)	1 (4)
No	0	41 (80)	50 (78)	18 (78)
VHL methylation status
Yes	0	5 (10)	5 (8)	4 (17)
No	1 (100)	45 (88)	54 (84)	18 (78)

Overall VHL gene inactivation status could = no, yes, fail, or incomplete. The status = “yes” if at least one VHL status (mutational, methylation, or deletion) = “yes”; = “fail” if VHL mutational status was of unknown significance; = “no” if all three were “no”; and = “incomplete” if all tests were not successful

CR Complete response, PD progressive disease, PR partial response, RECIST response evaluation criteria in solid tumors, SD stable disease, VHL Von Hippel–Lindau